• Citer

Development and Validation of an 18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography-Based Imaging Score to Predict 12-Week Life Expectancy in Advanced Chemorefractory Colorectal Cancer.

par Paquier, Zelda ;Dhont, Jennifer ;Guiot, Thomas ;Levillain, Hugo ;Critchi, Gabriela;Saúde Conde, Rita ;Sclafani, Francesco ;Flamen, Patrick ;Reynaert, Nick ;Woff, Erwin ;Hendlisz, Alain
Référence JCO Clinical Cancer Informatics, 9, page (e2400207)
Publication Publié, 2025-05

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Managing chemorefractory metastatic colorectal cancer (mCRC) requires a meticulous equilibrium between the efficacy and toxicity of interventions, a task compounded by the constrained life expectancy of the patient. While existing prognostic tools, such as the Colon Life nomogram, primarily focus on general patient conditions or a single diagnostic modality, they do not fully integrate the potential predictive value of multimodal data. This study aims to develop and validate an Imaging Score, integrating clinical and imaging features derived from whole-body 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography-computed tomography (PET-CT), predicting death probability within 12 weeks from treatment initiation for refractory disease.